Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evolus Expands Global Footprint With Introduction Of Nuceiva In Australia

Author: Benzinga Newsdesk | July 30, 2024 08:14am
  • Launching into this growth market1 as part of the company's geographic expansion strategy
  • Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva® (prabotulinumtoxinA).

Nuceiva® is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2.

Posted In: EOLS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist